Table 1 Demographic, clinicopathological, and hematological index of NSCLC patients in the training and validation cohorts

Age (median), n (%)

  < 59

103 (50.49%)

76 (37.25%)

27 (13.24%)

34 (49.28%)

26 (37.68%)

8 (11.59%)

  ≥ 59

101 (49.51%)

81 (37.71%)

20 (9.80%)

35 (50.72%)

28 (40.58)

7 (10.14%)

Sex, n (%)

 Male

171 (83.82%)

134 (65.69%)

37 (18.14%)

49 (71.00%)

37 (53.62%)

12 (17.39%)

 Female

33 (16.18%)

23 (11.27%)

10 (4.90%)

20 (29.00%)

17 (24.64%)

3 (4.35%)

Patient status

BMI, n (%)

  < 18.5

19 (9.31%)

7 (3.43%)

12 (5.88%)

3 (4.35%)

1 (1.45%)

2 (2.90%)

 18.5–24

121 (59.31%)

91 (44.61%)

30 (14.71%)

35 (50.72%)

29 (42.03%)

6 (8.70%)

  > 24

64 (31.38%)

59 (28.92%)

5 (2.45%)

31 (44.93%)

24 (34.78%)

7 (10.14%)

Alcohol, n (%)

 No

162 (79.41%)

123 (60.29%)

39 (19.12%)

56 (81.16%)

45 (65.22%)

11 (15.94%)

 Yes

42 (20.59%)

34 (16.67%)

8 (3.92%)

13 (18.84%)

9 (13.04%)

4 (5.80%)

Smoking, n (%)

 No

89 (43.63%)

70 (34.31%)

19 (9.31%)

38 (55.07%)

33 (47.83%)

5 (7.25%)

 Yes

115 (56.37%)

87 (42.65%)

28 (13.73%)

31 (44.93%)

21 (30.43%)

10 (14.495)

Histology, n (%)

 Adenocarcinoma

107 (52.45%)

83 (40.69%)

24 (11.76%)

48 (69.57%)

40 (57.97%)

8 (11.59%)

 Squamous cell carcinoma

97 (47.55%)

74 (36.27%)

23 (11.27%)

21 (30.43%)

14 (20.29%)

7 (10.14%)

No. of metastatic sites, n (%)

  < 2

141 (69.12%)

110 (53.92%)

21 (10.29%)

42 (60.87%)

35 (50.72%)

7 (10.14%)

  ≥ 2

63 (30.88%)

47 (23.04%)

26 (12.75%)

27 (39.13%)

19 (27.54%)

8 (11.59%)

Pleural metastasis, n (%)

 Absent

149 (73.04%)

124 (60.78%)

25 (12.25%)

42 (60.87%)

38 (55.07%)

4 (5.80%)

 Present

55 (26.96%)

33 (16.18%)

22 (10.78%)

27 (39.13%)

16 (23.19%)

11 (15.94%)

Lung metastasis, n (%)

 Absent

140 (68.63%)

107 (52.45%)

33 (16.18%)

50 (72.46%)

39 (56.52%)

11 (15.94%)

 Present

64 (31.37%)

50 (24.51%)

14 (6.86%)

19 (27.54%)

15 (21.74%)

4 (5.80%)

Brain metastasis, n (%)

 Absent

176 (86.27%)

134 (65.69%)

42 (20.59%)

61 (88.41%)

46 (66.67%)

15 (21.74%)

 Present

28 (13.73%)

23 (11.27%)

5 (2.45%)

8 (11.59%)

8 (11.59%)

0

Liver metastasis, n (%)

 Absent

179 (87.75%)

140 (68.63%)

39 (19.12%)

61 (88.41%)

47 (68.12%)

14 (20.29%)

 Present

25 (12.25%)

17 (8.33%)

8 (3.92%)

8 (11.59%)

7 (10.14%)

1 (1.45%)

Bone metastasis, n (%)

 Absent

153 (95.70%)

117 (57.35%)

36 (17.65%)

50 (72.50%)

41 (59.42%)

9 (13.04%)

 Present

51 (4.30%)

40 (19.61%)

11 (5.39%)

19 (27.50%)

13 (18.84%)

6 (8.70%)

WBC, 10⁹/L

7.48 (5.95–9.03)

7.56 (6.10–8.97)

6.93 (5.67–9.80)

7.21 (5.73–9.50)

7.09 (5.56–9.11)

8.29 (6.99–10.45)

Neutrophils, 10⁹/L

4.86 (3.79–6.51)

4.99 (3.79–6.35)

4.80 (3.67–7.50)

4.80 (3.60–6.70)

4.30 (3.32–5.70)

6.60 (4.55–7.90)

Lymphocytes, 10⁹/L

1.54 (1.14–1.96)

1.63 (1.20–2.11)

1.30 (1.10–1.65)

1.80 (1.10–2.10)

1.85 (1.24–2.22)

1.07 (0.85–1.50)

Monocytes, 10⁹/L

0.54 (0.42–0.70)

0.54 (0.43–0.70)

0.54 (0.40–0.7)

0.50 (0.40–0.70)

0.50 (0.40–0.70)

0.60 (0.50–0.70)

NLR

3.15 (2.10–4.57)

2.98 (2.01–4.38)

3.45 (2.30–6.67)

2.75 (1.96–5.00)

2.39 (1.69–3.94)

4.38 (3.16–9.21)

LMR

2.82 (1.92–4.00)

2.89 (2.00–4.04)

2.33 (1.85–3.41)

3.00 (1.94–4.48)

3.60 (2.05–4.80)

1.80 (1.20–2.84)

PLR

172.04 (126.97–250.69)

172.14 (127.27–254.09)

171.93 (133.07–249.52)

151.11 (113.81–244.44)

148.39 (110.16–228.89)

157.50 (125.90–261.11)

PLT, 10⁹/L

272.50 (219.25–356.00)

288.00 (223.00–371.00)

232.00 (197.50–280.00)

258.00 (207.00–327.00)

270.5 (211.5–325.75)

230.00 (161.00–289.50)

PT, s

11.70 (11.13–12.10)

11.60 (11.10–12.10)

11.70 (11.30–12.10)

11.60 (10.85–12.10)

11.50 (10.80–12.10)

11.80 (11.45–12.05)

APTT, s

26.15 (24.20–27.98)

26.10 (24.25–27.50)

26.8 (24.0–29.50)

25.50 (23.45–27.45)

24.80 (23.30–27.05)

27.50 (25.7–30.85)

Fbg, g/L

4.55 (3.59–5.75)

4.68 (3.58–5.81)

4.43 (3.64–5.22)

3.80 (3.29–5.02)

3.68 (3.24–5.17)

4.45 (3.44–4.98)

TT, s

17.10 (16.30–17.88)

17.00 (16.20–17.75)

17.60 (16.70–18.05)

17.40 (16.80–18.00)

17.45 (16.80–18.10)

17.10 (16.60–17.65)

CD3 + cells, %

68.67 (60.70–75.67)

69.28 (61.50–76.39)

66.25 (59.27–73.64)

70.50 (63.40–76.10)

69.40 (62.68–73.94)

76.40 (69.80–78.33)

CD3 + CD4 + cells, %

38.59 (30.20–43.30)

40.07 (31.57–44.90)

34.71 (28.05–40.08)

35.95 (29.25–44.45)

35.63 (29.18–41.93)

44.90 (32.00–46.70)

CD3 + CD8 + cells, %

25.57 (22.08–33.18)

25.86 (20.69–33.18)

25.35 (22.38–33.38)

26.90 (22.60–34.20)

26.90 (22.45–35.08)

28.80 (22.13–34.93)

B cells, %

8.02 (5.93–11.43)

9.11 (6.25–11.74)

7.15 (4.80–9.93)

9.15 (6.34–12.60)

9.15 (6.50–14.45)

8.75 (5.30–11.13)

CD3-CD16 + CD56 + cells, %

18.05 (12.93–25.80)

17.03 (11.67–24.28)

21.20 (16.58–28.40)

17.65 (11.65–20.99)

18.50 (13.45–21.32)

12.10 (9.18–17.48)

Treg cells, %

23.45 (17.55–31.25)

22.95 (17.13–28.45)

25.00 (19.18–37.43)

20.15 (14.90–25.70)

18.60 (14.13–24.50)

31.75 (20.75–40.28)

CD8 + CD25 + cells, %

7.65 (4.28–11.18)

8.95 (6.1–12.43)

5.25 (3.15–8.83)

7.15 (4.75–10.30)

725 (4.93–10.48)

5.90 (4.55–8.45)

TNM stage, n (%)

Stage II

5 (2.45%)

2 (0.98%)

3 (1.47%)

0

0

0

Stage III

55 (26.96%)

50 (24.51%)

5 (2.45%)

21 (30.43%)

18 (26.09%)

3 (4.35%)

Stage IV

144 (70.59%)

105 (51.47%)

79 (38.73%)

48 (69.57%)

36 (52.17%)

12 (17.39%)